Welcome to our dedicated page for ZyVersa Therapeutics news (Ticker: $ZVSA), a resource for investors and traders seeking the latest updates and insights on ZyVersa Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ZyVersa Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ZyVersa Therapeutics's position in the market.
ZyVersa Therapeutics (Nasdaq: ZVSA) announced its Q1-2024 financial results and provided a business update. Net losses were $2.8 million, a 20.2% improvement from Q1-2023. The company has $2.0 million in cash, sufficient for month-to-month operations but will need additional financing. Key developments include the initiation of a Phase 2a clinical trial for Cholesterol Efflux MediatorTM VAR 200 in diabetic kidney disease and upcoming GLP toxicology studies for Inflammasome ASC Inhibitor IC 100. Other milestones include preclinical data readouts and collaborations for IC 100, focusing on atherosclerosis and obesity-related conditions. ZyVersa raised $2.7 million through warrant exercises.
ZyVersa Therapeutics announced that CEO Stephen C. Glover will participate in the 2024 BIO International Convention in San Diego from June 3-6, 2024. ZyVersa is developing treatments for renal and inflammatory diseases using two proprietary technologies: the Cholesterol Efflux Mediator™ VAR 200 and the Inflammasome ASC Inhibitor IC 100. The company plans to start a Phase 2a clinical trial for VAR 200 in diabetic kidney disease in the first half of 2024 and is conducting preclinical studies for expanding IC 100's indications to atherosclerosis, obesity, and Parkinson’s disease. An IND filing for IC 100 is expected by year-end, with Phase 1 trials starting in Q1-2025. Glover will be available for one-on-one meetings to discuss these developments.
ZyVersa Therapeutics, Inc. announces a publication highlighting the role of inflammasome-mediated inflammation in Alzheimer's Disease (AD) and its impact on heart health. The company is developing Inflammasome ASC Inhibitor IC 100 to target multiple inflammasomes and reduce inflammation. The research indicates a potential therapeutic target for cardiac comorbidities in AD and beyond.
